HealthThe Motley Foolabout 4 hours ago
VC Insider Buys 25,000 Nuvation Bio Shares
1 min read
A veteran pharma venture capital insider purchased 25,000 shares of Nuvation Bio as its new drug gains momentum. The insider's buy signals confidence in the company's pipeline. Nuvation Bio is developing therapies for oncology.
Level
Hype check
Tap to vote and see what everyone thinks.
